# OnCo record imlunestrant (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/imlunestrant/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "imlunestrant" ;
  schema:name "Imlunestrant"@en ;
  schema:description "Imlunestrant is Lilly's oral oestrogen-receptor degrader, approved in 2025 for ESR1-mutant breast cancer and shown to work with abemaciclib regardless of mutation."@en ;
  schema:url <https://onco.cc/drugs/imlunestrant/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Imlunestrant> ;
  onco:status "approved" ;
  onco:modality "Oral SERD" ;
  schema:alternateName "Inluriyo" ;
  onco:approval "US 2025: ER+/HER2- ESR1-mutated advanced breast cancer after ≥1 line of endocrine therapy", "EU 2026: ESR1-mutant ER+/HER2- mBC; 9 Jan 2026" ;
  onco:related <https://onco.cc/biomarkers/esr1-mutation-ctdna/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/oral-serd/> ;
  onco:trials <https://onco.cc/trials/ember-3/>, <https://onco.cc/trials/nct07287098/>, <https://onco.cc/trials/nct05514054/> .